Compounds > benzylidene glucose
Page last updated: 2024-12-07

benzylidene glucose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID100089
CHEMBL ID1986984
SCHEMBL ID12032224
MeSH IDM0061946

Synonyms (26)

Synonym
NCI60_002922
nsc-333861
nsc333861
mls003170843 ,
.alpha.-d-glucopyranose,6-o-(phenylmethylene)-
25152-90-3
4,6-o-benzylidene-d-galactose
nsc243486
nsc-243486
OPREA1_571051
benzylidene glucose
2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine-6,7,8-triol
FT-0654761
FT-0662806
smr001874760
.alpha.-d-glucopyranose, 4,6-o-(phenylmethylene)-
alpha-d-glucopyranose, 4,6-o-(phenylmethylene)-
p-1013
nsc 333861
CHEMBL1986984
SCHEMBL12032224
AKOS030212689
4-o,6-o-benzylidene-alpha-d-glucopyranose
SY224230
mfcd00057743
A919199

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" It was found that BG rapidly disappeared with a half-life (t1/2) on the order of 10 min."( In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats.
Børretzen, B; Dornish, JM; Larsen, RO; Pettersen, EO; Schwarze, PE, 1990)		0.28

Bioavailability

ExcerptReferenceRelevance
" In this study we compared the bioavailability of BG and P-1013, since both intraperitoneal and, especially, oral administration of the drugs would be a great advantage."( The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.
Dornish, JM; Dunsaed, CB; Pettersen, EO, 1995)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's6 (54.55)18.2507
2000's2 (18.18)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzaldehyde
[no description available]		1.9610benzaldehydesEC 3.1.1.3 (triacylglycerol lipase) inhibitor;
EC 3.5.5.1 (nitrilase) inhibitor;
flavouring agent;
fragrance;
odorant receptor agonist;
plant metabolite
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9810dihydrogen
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0510
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9810
Carcinoma, Anaplastic
[description not available]		02.3820
Cancer of Ovary
[description not available]		01.9810
Cancer of Pancreas
[description not available]		02.3820
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.3820
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		01.9810
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		01.9810
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.3820
Cancer of Colon
[description not available]		01.9710
Cancer of Liver
[description not available]		01.9710
Cancer of Lung
[description not available]		01.9710
Cancer of Prostate
[description not available]		01.9710
Cancer of Stomach
[description not available]		01.9710
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9710
Liver Neoplasms
Tumors or cancer of the LIVER.		01.9710
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9710
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9710
Stomach Neoplasms
Tumors or cancer of the STOMACH.		01.9710
Adenocarcinoma, Basal Cell
[description not available]		01.9710
Colorectal Cancer
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9710
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		01.9710
Benign Neoplasms
[description not available]		01.9610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9610